Information Provided By: 
Fly News Breaks for January 2, 2020
GILD
Jan 2, 2020 | 07:08 EDT
Piper Jaffray analyst Edward Tenthoff noted that Gilead raised list prices by 4.8% on the company's top five selling HIV antiviral drugs, which he notes is in-line with last year's price increases. Tenthoff, who said the HIV drug price hikes "appear responsible" given that they are in-line with the median 5% price increase taken by large pharma for 2020 and "well below" the high single-digit hikes observed with some other companies, keeps a Neutral rating on Gilead shares.
News For GILD From the Last 2 Days
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
